TME Pharma NV (XPAR:ALTME) Stock Based Compensation: €0.09 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is TME Pharma NV Stock Based Compensation?

TME Pharma NV XPAR:ALTME +3.00% Stock Based Compensation is €0.09 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

TME Pharma NV's Stock Based Compensation for the six months ended in Dec. 2025 was €0.16 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was €0.09 Mil.

TME Pharma NV Stock Based Compensation Related Terms

TME Pharma NV Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for TME Pharma NV's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TME Pharma NV Stock Based Compensation Chart

TME Pharma NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.59 0.40 0.31 0.09

TME Pharma NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.21 0.10 -0.08 0.16

TME Pharma NV Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.09 Mil.

What does a Stock Based Compensation of €0.09 Mil mean?
TME Pharma NV (XPAR:ALTME) has a Stock Based Compensation of €0.09 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for TME Pharma NV and its competitors.
Is TME Pharma NV's Stock Based Compensation too high?
TME Pharma NV's current Stock Based Compensation is €0.09 Mil.
How does TME Pharma NV's Stock Based Compensation compare to VRTX and REGN?
TME Pharma NV's Stock Based Compensation of €0.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for TME Pharma NV and its competitors. TME Pharma NV's current Stock Based Compensation is €0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TME Pharma NV stock overvalued right now?
TME Pharma NV (XPAR:ALTME) has a current Stock Based Compensation of €0.09 Mil. The current Stock Based Compensation is €0.09 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For TME Pharma NV (XPAR:ALTME), the current Stock Based Compensation is €0.09 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TME Pharma NV Business Description

Other Exchanges 0N6A:Germany
Address Max-Dohrn-Strasse 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.